

Optic Nerves Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators therapy and Others), Indication (Glaucoma, Optic Neuritis and Others), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027

<https://marketpublishers.com/r/OB28580EFA35EN.html>

Date: July 2023

Pages: 145

Price: US\$ 4,500.00 (Single User License)

ID: OB28580EFA35EN

Abstracts

The Optic Nerves are the cranial nerves which connect the retinal cells to the optic chiasm. In the retina photoreceptor cells are present which receive light and transmit it to the brain in the form of electric impulses through the optic nerves. Based on the nature and area of the injury, dysfunction or damage to the optic nerves might lead to visual loss. One can develop vision impairment in either one or both eyes. A key factor fueling the market growth is a rise in the lifestyle diseases such as diabetes, blood pressure, hypertension, etc. owing to the adoption of a inactive lifestyle unhealthy diet, dearth of physical activities, etc. which further increase the possibilities of multiple sclerosis resulting in the optic neuritis. Owing to this, there is a surge in the ratio of people requiring treatment for the disease. On the contrary, the adverse effects of using drugs for disorder treatment may limit the optic nerves disorder treatment market growth. The Optic Nerves Disorder Treatment Market is expected to rise at a rate of 4.5% CAGR by 2027.

Optic Nerves Disorder Treatment Market based on Treatment Type

Steroidal Therapy

Immunomodulators therapy

Others

Optic Nerves Disorder Treatment Market based on Indication

- Glaucoma
- Optic Neuritis
- Others

Optic Nerves Disorder Treatment Market based on Distribution Channel

- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers

Optic Nerves Disorder Treatment Market based on Geography

- North America
- Europe
- Asia Pacific
- Rest of World

The market based on treatment type is further segmented as Steroidal Therapy, Immunomodulators therapy and Others. The Immunomodulators therapy segment is likely to hold the highest share in the market. The highest share of the segment is due to the rise in the research and development activities for the manufacturing of immunomodulators for optic nerve disorder treatments coupled with the surge in number of key players has resulted increase in the launch of new drugs which further boost the optic nerves disorder treatment market growth.

Based on the indication the market is categorized as Glaucoma, Optic Neuritis and Others. The glaucoma segment held the significant share in the market owing to a surge in incidence of open angle glaucoma. In addition to this, the rise in number of approvals for drugs for the treatment of open angle glaucoma is projected to boost the optic nerves disorder treatment market growth.

Then further based on distribution channel, the market is bifurcated into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The drug stores and retail pharmacies segment has the maximum share in the optic nerves disorder treatment market. Rising number of independent pharmacies and chains coupled with the availability of several rare disease medications in supermarkets and mass retailers

are the reasons for segment growth.

In the regional market of optic nerves disorder treatment market, North America has acquired the major share in the market. Key factors propelling the growth of the optic nerves disorder treatment market are the substantial presence of leading pharmaceutical and biopharmaceutical companies in the North American region.

E-commerce (electronic commerce) has become a significant tool for small and large businesses worldwide, owing to the increase in preference of consumers for online shopping over conventional purchasing methods. This is ascribed to further supports for global market growth. The demand for optic nerve disorder treatment products is not only constrained to developed nations but is also being witnessed in developing nations, such as China, Brazil, and India, which boosts the growth of the global optic nerve disorder treatment market.

Prominent players operating in the market are Teva Pharmaceutical Industries Ltd, Bausch Health Companies, Inc., Santen Pharmaceutical Co. Ltd., AbbVie Inc., Novartis AG, Aerie Pharmaceuticals, Inc., Cipla Ltd, Merck & Co. Inc., mallinckrodt pharmaceuticals, and Pfizer, Inc.

As a result, there is significant scope for the optic nerve disorder treatment in the present scenario. This is due to the various factors such as advancements in the medical technology which have resulted in the development of new and more effective treatments for optic nerve disorder.

This research segments the market completely and gives the nearest evaluations of the complete market size, along with that of the sub segments among major regions.

This report gives insightful analysis of the market and gives a comprehensive understanding of the market and its commercial landscape.

Provides the information about the market strategies which are being adopted by the competitors and leading organizations.

This report provides the perception of the future outlook and prospects for market analysis and forecast.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

2.1. Industry Overview

2.2. Industry Trends

3. MARKET SNAPSHOT

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. MARKET CHARACTERISTICS

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. TREATMENT TYPE: MARKET SIZE & ANALYSIS

5.1. Overview

5.2. Steroidal Therapy

5.3. Immunomodulators therapy

5.4. Others

6. INDICATION: MARKET SIZE & ANALYSIS

6.1. Overview

6.2. Glaucoma

6.3. Optic Neuritis

6.4. Others

7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS

- 7.1. Overview
- 7.2. Hospital Pharmacies
- 7.3. Drug Stores and Retail Pharmacies
- 7.4. Online Providers

8. GEOGRAPHY: MARKET SIZE & ANALYSIS

- 8.1. Overview
- 8.2. North America
- 8.3. Europe
- 8.4. Asia Pacific
- 8.5. Rest of the World

9. COMPETITIVE LANDSCAPE

- 9.1. Competitor Comparison Analysis
- 9.2. Market Developments
 - 9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
 - 9.2.2. Product Launches and execution

10. VENDOR PROFILES

- 10.1. Teva Pharmaceutical Industries Ltd
 - 10.1.1. Overview
 - 10.1.2. Financial Overview
 - 10.1.3. Product Offerings
 - 10.1.4. Developments
 - 10.1.5. Business Strategy
- 10.2. Bausch Health Companies, Inc.
 - 10.2.1. Overview
 - 10.2.2. Financial Overview
 - 10.2.3. Product Offerings
 - 10.2.4. Developments
 - 10.2.5. Business Strategy
- 10.3. Santen Pharmaceutical Co. Ltd.
 - 10.3.1. Overview

- 10.3.2. Financial Overview
- 10.3.3. Product Offerings
- 10.3.4. Developments
- 10.3.5. Business Strategy
- 10.4. AbbVie Inc.
 - 10.4.1. Overview
 - 10.4.2. Financial Overview
 - 10.4.3. Product Offerings
 - 10.4.4. Developments
 - 10.4.5. Business Strategy
- 10.5. Novartis AG
 - 10.5.1. Overview
 - 10.5.2. Financial Overview
 - 10.5.3. Product Offerings
 - 10.5.4. Developments
 - 10.5.5. Business Strategy
- 10.6. Aerie Pharmaceuticals, Inc.
 - 10.6.1. Overview
 - 10.6.2. Financial Overview
 - 10.6.3. Product Offerings
 - 10.6.4. Developments
 - 10.6.5. Business Strategy
- 10.7. Cipla Ltd
 - 10.7.1. Overview
 - 10.7.2. Financial Overview
 - 10.7.3. Product Offerings
 - 10.7.4. Developments
 - 10.7.5. Business Strategy
- 10.8. Merck & Co. Inc.
 - 10.8.1. Overview
 - 10.8.2. Financial Overview
 - 10.8.3. Product Offerings
 - 10.8.4. Developments
 - 10.8.5. Business Strategy
- 10.9. mallinckrodt pharmaceuticals
 - 10.9.1. Overview
 - 10.9.2. Financial Overview
 - 10.9.3. Product Offerings
 - 10.9.4. Developments

- 10.9.5. Business Strategy
- 10.10. Pfizer, Inc
 - 10.10.1. Overview
 - 10.10.2. Financial Overview
 - 10.10.3. Product Offerings
 - 10.10.4. Developments
 - 10.10.5. Business Strategy

11. ANALYST OPINION

12. ANNEXURE

- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
 - 12.3.1. Data Collation and In-house Estimation
 - 12.3.2. Market Triangulation
 - 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR STEROIDAL THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR IMMUNOMODULATORS THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR GLAUCOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR OPTIC NEURITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 15. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 16. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 17. U.S OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 18. U.S OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 19. U.S OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 20. CANADA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 21. CANADA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 22. CANADA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 23. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 24. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 25. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 26. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 27. GERMANY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 28. GERMANY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 29. GERMANY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 30. U.K OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 31. U.K OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 32. U.K OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 33. FRANCE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 34. FRANCE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 35. FRANCE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 36. ITALY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 37. ITALY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY

INDICATION, 2021-2027 (USD BILLION)

TABLE 38. ITALY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 39. SPAIN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 40. SPAIN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 41. SPAIN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 42. ROE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 43. ROE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 44. ROE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 45. ASIA PACIFIC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFIC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFIC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 48. ASIA PACIFIC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 49. CHINA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 50. CHINA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 51. CHINA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 52. INDIA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 53. INDIA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 54. INDIA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 55. JAPAN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 56. JAPAN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 57. JAPAN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 58. REST OF APAC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 60. REST OF APAC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 61. REST OF WORLD OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)

TABLE 63. REST OF WORLD OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 64. TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIALS

TABLE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS & SERVICES

TABLE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS

TABLE 67. BAUSCH HEALTH COMPANIES, INC.: FINANCIALS

TABLE 68. BAUSCH HEALTH COMPANIES, INC.: PRODUCTS & SERVICES

TABLE 69. BAUSCH HEALTH COMPANIES, INC.: RECENT DEVELOPMENTS

TABLE 70. SANTEN PHARMACEUTICAL CO. LTD.: FINANCIALS

TABLE 71. SANTEN PHARMACEUTICAL CO. LTD.: PRODUCTS & SERVICES

TABLE 72. SANTEN PHARMACEUTICAL CO. LTD.: RECENT DEVELOPMENTS

TABLE 73. ABBVIE INC.: FINANCIALS

TABLE 74. ABBVIE INC.: PRODUCTS & SERVICES

TABLE 75. ABBVIE INC.: RECENT DEVELOPMENTS

TABLE 76. NOVARTIS AG: FINANCIALS

TABLE 77. NOVARTIS AG: PRODUCTS & SERVICES

TABLE 78. NOVARTIS AG: RECENT DEVELOPMENTS

TABLE 79. AERIE PHARMACEUTICALS, INC.: FINANCIALS

TABLE 80. AERIE PHARMACEUTICALS, INC.: PRODUCTS & SERVICES

TABLE 81. AERIE PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS

TABLE 82. CIPLA LTD: FINANCIALS

TABLE 83. CIPLA LTD: PRODUCTS & SERVICES

TABLE 84. CIPLA LTD: RECENT DEVELOPMENTS

TABLE 85. MERCK & CO. INC.: FINANCIALS

TABLE 86. MERCK & CO. INC.: PRODUCTS & SERVICES

TABLE 87. MERCK & CO. INC.: RECENT DEVELOPMENTS

TABLE 88. MALLINCKRODT PHARMACEUTICALS: FINANCIALS

TABLE 89. MALLINCKRODT PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 90. MALLINCKRODT PHARMACEUTICALS: RECENT DEVELOPMENTS
TABLE 91. PFIZER, INC.: FINANCIALS
TABLE 92. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 93. PFIZER, INC.: RECENT DEVELOPMENTS

I would like to order

Product name: Optic Nerves Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators therapy and Others), Indication (Glaucoma, Optic Neuritis and Others), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027

Product link: <https://marketpublishers.com/r/OB28580EFA35EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OB28580EFA35EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970